登录 | 注册    关注公众号  
微信公众号
搜索
>产品&服务 > 激动性靶点蛋白加速免疫疗法发展

激动性靶点蛋白加速免疫疗法发展

激动性靶点蛋白加速免疫疗法发展
背景
2018年诺贝尔生理学或医学奖颁给了美国免疫学家詹姆斯·艾利森(James Allison)和日本免疫学家本庶佑(Tasuku Honjo),他们的研究发现证实了免疫检查点是免疫系统的关键调节器。这些免疫检查点包括共抑制和共刺激受体(激活性受体),它们与配体结合后能够抑制或激活免疫细胞的功能。
目前已有多种免疫检查点抑制剂药物处于研发阶段及应用于临床,它们的作用是阻止“关闭”信号到达免疫系统。但是如果免疫反应不够强,需要利用多种共刺激信号来激活T细胞,使用共刺激免疫受体开发激动剂。与共抑制受体相对,共刺激受体(激活性受体)的作用是增强免疫细胞的抗肿瘤活性。
目前,研究激动型抗体的靶点主要集中在免疫球蛋白B7-CD28超家族和肿瘤坏死因子受体(TNFR)超家族上。B7-CD28信号是促进T细胞激活和细胞因子释放的主要共刺激信号。4-1BB、GITR、OX40、ICOS、CD27和其他肿瘤坏死因子超家族(TNF-SF)的受体可以与TCR信号协同作用,增强T细胞反应和生存能力。
因此,开发靶向TNFSF和B7家族共刺激受体激动剂成为肿瘤免疫领域又一热门赛道,可以扩宽现有治疗范围,并提高其疗效。这些免疫激动剂的开发为免疫治疗的未来提供了更为广泛的选择。
ACROBiosystems百普赛斯已开发了一系列针对TNFSFB7-CD28家族免疫共刺激分子的相关产品,包括靶点蛋白、过表达细胞系、报告基因细胞系和抑制剂筛选试剂盒等,可满足激动性抗体从抗体制备、筛选、生产到质控全流程,确保提供最佳的试剂和工具来助力您的激动剂药物研发进程。
产品列表
  • 激动性靶点蛋白
  • 过表达细胞系
  • 报告基因细胞系
  • 抑制剂筛选试剂盒
分子 货号 描述
OX40 Ligand CHEK-ATP054 HEK293/Human OX40 Ligand / TNFSF4 Stable Cell Line
OX40 CHEK-ATP053 HEK293/Human OX40 / TNFRSF4 / CD134 Stable Cell Line
4-1BB Ligand CHEK-ATP039 HEK293/Human 4-1BB Ligand / TNFSF9 Stable Cell Line
4-1BB CHEK-ATP038 HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line
分子 货号 描述
4-1BB CHEK-ATF073 Human 4-1BB (Luc) HEK293 Reporter Cell
CD40 CHEK-ATF097 Human CD40 (Luc) HEK293 Reporter Cell
分子 货号 描述
CD27 EP-121 CD27L [Biotinylated] : CD27 Inhibitor Screening ELISA Kit
CD30 EP-135 CD30 [Biotinylated] : CD30L Inhibitor Screening ELISA Kit
CD28 EP-150 CD28 : B7-1 [Biotinylated] Inhibitor Screening ELISA Kit
CD28 EP-151 CD28 : B7-2 [Biotinylated] Inhibitor Screening ELISA Kit
产品特点

天然构象及高纯度经SEC-MALS验证

多种技术平台验证与配(受)体或抗体的结合活性

多种属多标签供选择,包括Human、Mouse、Rat、Cynomolgus等,可用于不同种属交叉实验。

我们正在不断探索更多的工具,以帮助您加速研发进程!

4-1BB、OX40等过表达细胞系及4-1BB、CD40等报告基因细胞系!

CD27/CD27L等抑制剂筛选试剂盒!

验证数据
天然多聚体结构及高纯度经SEC-MALS验证
天然多聚体结构及高纯度经SEC-MALS验证

The purity of Human OX40 Ligand, His Tag (active trimer) (Cat. No. OXL-H52Q8) is more than 95% in HP-SEC, and the molecular weight of this protein is around 60-80 kDa verified by SEC-MALS.

天然多聚体结构及高纯度经SEC-MALS验证

The purity of Human / Cynomolgus / Rhesus macaque CD28 Protein, His Tag (Cat. No. CD8-H52H3) is more than 90% and the molecular weight of this protein is around 65-75 kDa verified by SEC-MALS.

高生物活性经与受体或抗体结合验证
高生物活性经与受体或抗体结合验证

Immobilized Human 4-1BB, His Tag (Cat. No. 41B-H52Hc) at 1 μg/mL (100 μL/well) can bind Utomilumab with a linear range of 0.1-4 ng/mL (Routinely tested).


申请 Protocol

高生物活性经与受体或抗体结合验证

Human UreluMab captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human 4-1BB, His Tag (Cat. No. 41B-H52Hc) with an affinity constant of 3.59 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).

申请 Protocol

高生物活性经与受体或抗体结合验证

FACS assay shows that Monoclonal UreluMab antibody, Human IgG4 can bind to HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line (CHEK-ATP038). HEK293/Human 4-1BB / TNFRSF9 Stable Cell Line was red line, Negative control HEK293 cells was grey line(QC tested).

申请 Protocol

细胞功能活性经FACS及cell-based assay验证
细胞功能活性经FACS及cell-based assay验证

Flow Cytometry assay shows that Human 4-1BB Protein, Mouse IgG2a Fc Tag (Cat. No. 41B-H5256) can bind to 293T cells overexpressing Human 4-1BBL.The concentration of 4-1BB used is 0.03 μg/mL (Routinely tested).

申请 Protocol

细胞功能活性经FACS及cell-based assay验证

Human CD40 Ligand, His,Flag Tag (Cat. No. CDL-H52Db) stimulates secretion of IL-6 by human B cells. The ED50 for this effect is 18.76-19.45 ng/mL in the presence of 5 ng/mL of Recombinant Human IL 4 (Routinely tested).

申请 Protocol

细胞功能活性经FACS及cell-based assay验证

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).


申请 Protocol

参考文献
  • 1. Choi Y, Shi Y, Haymaker CL, Naing A, Ciliberto G, Hajjar J. T-cell agonists in cancer immunotherapy. J Immunother Cancer. 2020 Oct;8(2):e000966. doi: 10.1136/jitc-2020-000966.

  • 2. Elgueta R, Benson MJ, de Vries VC, et al.. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev 2009;229:152–72.

ACRO质量管理体系

消息提示

请输入您的联系方式,再点击提交!

确定